CGON – cg oncology, inc. (US:NASDAQ)
Stock Stats
News
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec [Yahoo! Finance]
CG Oncology Initiates Expanded Access Program for Cretostimogene Grenadenorepvec
CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC
CG Oncology, Inc. (NASDAQ: CGON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
CG Oncology to Present Positive Final Results from Phase 2 CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive High-Risk NMIBC at ASCO 2024 Annual Meeting [Yahoo! Finance]
Form 8-K CG Oncology, Inc. For: May 24
Form 4 CG Oncology, Inc. For: May 15 Filed by: Patterson Joshua F.
Form 3 CG Oncology, Inc. For: May 13 Filed by: Patterson Joshua F.
Form 8-K CG Oncology, Inc. For: May 09
Form 10-Q CG Oncology, Inc. For: Mar 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.